Skip to main content
. Author manuscript; available in PMC: 2020 Feb 17.
Published in final edited form as: Nano Lett. 2019 Feb 18;19(3):1883–1891. doi: 10.1021/acs.nanolett.8b04970

Figure 5.

Figure 5.

Functional benefits of P-CD34 therapy. (A) Representative Masson’s trichrome-stained myocardial sections 4 weeks after treatment. (B) Quantitative analyses of viable myocardium from the Masson’s trichrome images (n = 6 animals per group). (C, D) Left ventricular end diastolic (C) and end systolic (D) volumes (LVEDV and LVESV) measured by echocardiography at 4 weeks (n = 6 animals per group). (E, F) Left ventricular fractional shortening (LVFS) and ejection fractions (LVEFs) were measured by echocardiography at baseline and 4 weeks later. (n = 6 animals per group). All data are presented as mean plus or minus the standard deviation. Single asterisks indicated P-CD34 groups vs other groups and P < 0.05.